Goldman Sachs analysts added Abbott (ABT) to the firm’s US Conviction List as part of its monthly update. The company is nearing an inflection in organic revenue growth, driven by a pipeline of new products, the analyst tells investors in a research note. Goldman has a Buy rating on the shares with a $157 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT: